Status:
UNKNOWN
Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction
Lead Sponsor:
Clinical Hospital Centre Zagreb
Collaborating Sponsors:
University of Zagreb School of Medicine
Croatian Science Foundation
Conditions:
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Eligibility:
All Genders
18+ years
Brief Summary
The research is planned as a prospective nested case-control study. The plan is to recruit about 1,200 consecutive subjects whose pharmacotherapy involves the drug(s) of interest within 4.5 years. The...
Eligibility Criteria
Inclusion
- a) age 18 years or older; b) a new indication for the administration of any of the medicinal products of primary interest (NOAC, clopidogrel, prasugrel, ticagrelor, statins) for which at least a 3-month administration is predicted; c) signed informed consent (for repeated evaluations and donation of blood samples for genetic and eventual pharmacokinetic analysis).
Exclusion
- the existence of contraindications to the medicines of primary interest.
Key Trial Info
Start Date :
December 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 14 2025
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT05307718
Start Date
December 15 2020
End Date
December 14 2025
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UHC Zagreb
Zagreb, Croatia, 10000